ProKidney focuses on innovative treatments for chronic kidney disease (CKD). Their lead product candidate, rilparencel (formerly known as REACT®), is an autologous cell therapy designed to preserve kidney function and potentially delay or eliminate the need for dialysis. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and is currently undergoing Phase 3 clinical trials for patients with Stage 3b and 4 CKD caused by type 2 diabetes. ProKidney is committed to addressing the high unmet needs in CKD treatment, offering hope to millions affected by this progressive disease.